2023-03-31 15:02:41 ET
- Journey Medical press release ( NASDAQ: DERM ): FY Non-GAAP EPS of -$0.42.
- Revenue of $73.7M (+16.8% Y/Y) misses by $0.58M .
- Selling, general and administrative expenses were $59.5 million for the full year 2022, compared to $39.8 million for 2021.
- Research and development costs were $10.9 million for the full year 2022, compared to $16.6 million for the full year 2021. The full year 2021 included $13.8 million for the license acquisition of DFD-29.
For further details see:
Journey Medical Non-GAAP EPS of -$0.42, revenue of $73.7M misses by $0.58M